Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-10-03
2006-10-03
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S088000, C544S243000
Reexamination Certificate
active
07115592
ABSTRACT:
Novel compounds are provided having formula (I)whereR1, R2, R3, R4, Z, X and * are defined herein. Also provided are antiviral methods for use and processes for synthesis of the compounds of formula (I).
REFERENCES:
patent: 4659825 (1987-04-01), Holy et al.
patent: 4724233 (1988-02-01), De Clercq et al.
patent: 4740365 (1988-04-01), Yukimatsu et al.
patent: 4808716 (1989-02-01), Holy et al.
patent: 5098443 (1992-03-01), Parel et al.
patent: 5141752 (1992-08-01), Ayer et al.
patent: 5142051 (1992-08-01), Holy et al.
patent: 5208221 (1993-05-01), Kim et al.
patent: 5302585 (1994-04-01), Yu et al.
patent: 5352786 (1994-10-01), Jindrich et al.
patent: 5356886 (1994-10-01), Harnden et al.
patent: 5952375 (1999-09-01), Bischofberger et al.
patent: 6818633 (2004-11-01), Balzarini et al.
patent: 0 269 947 (1988-06-01), None
patent: 0 369 409 (1990-05-01), None
patent: 0 398 231 (1990-11-01), None
patent: 0 434 450 (1991-06-01), None
patent: 0 454 427 (1991-10-01), None
patent: 0 468 119 (1992-01-01), None
patent: 0 481 214 (1992-04-01), None
patent: 0 618 214 (1994-10-01), None
patent: 0 630 381 (1994-12-01), None
patent: WO 92/14450 (1992-09-01), None
patent: WO 94/03467 (1994-02-01), None
patent: WO 95/07920 (1995-03-01), None
patent: WO 96/33200 (1996-10-01), None
patent: WO 98/04569 (1998-02-01), None
patent: WO 03/002580 (2003-01-01), None
Goff, PubMed Abstract (J Gene Med 3(6):517-28), Nov.-Dec. 2001.
Bosseray et al., PubMed Abstract (Pathol Biol (Paris) 50(8):483-92), Oct. 2002.
Razonable et al., PubMed Abstract (Herpes 10(3):60-5), Dec. 2003.
Douglas, Jr. Introduction to Viral Diseases, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-47, 1996.
Balzarini et al, “Differential Antiherpesvirus and Antiretrovirus Effects of the (S) and (R) Enantiomers of Acyclic Nucleoside Phosphonates: Potent and Selective In Vitro and In Vivo Antiretrovirus Activities of (R)-9-(2- Phosphonomethoxypropyl)-2,6-Diaminopurine”, 37(2):332-338, AIDS, 1993.
Balzarini et al., “9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys”, 5:21-28, AIDS, 1991.
Cihlar et al., “Transport of 9-(2-Phosphonomethoxyethyl)Adenine across Plasma Membrane of HeLa S3 Cells Is Protein Mediated”, 39(1):117-124, Antimicro AG & Chemo, 1995.
De Clercq et al, “Moloney Sarcoma Virus-Induced Tumors in Mice: Inhibition or Stiumation . . . ”, 137:590-594, Proc Soc Exp Biol Med, 1971.
Egberink et al, “Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine”, 87:3087-3091, Proc Natl Acad Sci, 1990.
Eger et al., “Synthesis of New Acyclic Pyrimidine Nucleoside Analogs as Potential Antiviral Drugs”, 37:3057-3061, J Med Chem, 1994.
Franchetti et al, “Acyclic Nucleotides Related To Clitocine: Synthesis and Anti-HIV Activity”, 14(3-5):607-614, Nucls & Nuclt, 1995.
Greene et al, “Protection For The Hydroxyl Group, Including 1,2- and 1, 3-Diols”, 2:10-142, Protective Groups in Organic Synthesis (2nd Ed.) (John Wiley & Sons), 1991.
Greene et al, “Protection For The Amino Acids”, 7:309-405, Protective Groups in Organic Synthesis (2nd Ed.) (John Wiley & Sons), 1991.
Hartmann et al., “In vitro activity of acyclic nucleoside phosphonate derivatives against feline immunodeficiency virus in Crandell feline kidney cells and feline peripheral blood lymphocytes”, 5(1):13-19, Antiviral Chem & Chemo, 1994.
Holy et al., “Phosphonylmethyl Ethers of Nucleosides and Their Acyclic Analogues”, 401:51-71, Nucleotide Analogues, 1989.
Holy et al., “Synthesis of quaternary 1-[2-(phosphonomethoxy)ethyl]derivatives of 2,4-diaminopyrimidine and related acyclic nucleotide analogs”, 64:242-256, Collect Czech Chem Commun, 1999.
Holy, A., “Structure-Activity Studies in the Series of Acyclic Nucleotide Analogues”, 38(10):457-462, KEM IND, 1989.
Middleton et al, “Cyanocarbon Chemistry”, 80(11):2788-2795, J Am Chem Soc, 1958.
Middleton et al, “Cyanocarbon Chemistry. IX. Heterocyclic Compounds from Dicyanoketene Acetls”, 80:2829-2832, J Am Chem Soc, 1958.
Popovic et al, “Detection, Isolation, and Continuous Production of Cytopathic Retrovirus(HTLV-III)from Patients with AIDS and Pre-AIDS”, 224:497-500, SCIENCE, 1984.
Thormar et al, “Inhibitory effect of 9-(2-phosphonylethoxyethyl) adenine on visna virus infection in lambs: A model for in vivo testing of candidate anti-human immunodeficiency virus drugs”, 93:3283-3287, Proc Natl Acad Sci, 1995.
Van Laethem et al, “Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype”, 15:553-561, AIDS, 2001.
Wormstadt et al, “Synthesis of Acyclic Nucleoside Phosphonate as Antiviral Compounds”, 37:1187-1191, J Het Chem, 2000.
Balzarini Jan M. R.
De Clercq Erik D. A.
Hockova Dana
Holy Antonin
Biochemistry of the Academy of Sciences of the Czech Republic
Bosse Mark L.
Institute of Organic Chemistry
Rao Deepak
LandOfFree
Phosphonate substituted pyrimidine compounds and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphonate substituted pyrimidine compounds and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphonate substituted pyrimidine compounds and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3621218